Mydayis

SKIP-FOR-NOW for Dylan with HIGH confidence. Mydayis is the same mixed amphetamine salts chemical as Adderall — so the entire parent skip rationale (brain-development concern at 20, no ADHD diagnosis, appetite suppression vs MMA calories, no significant healthy-adult cognitive enhancement signal) carries over unchanged — plus a 16-hour duration profile that is the worst possible fit for a 20-year-old late chronotype currently migrating from 2-3 AM bedtime to midnight. Sleep onset would be materially compromised even with 7 AM dosing. Refer to parent: see adderall.md. Mydayis adds nothing Dylan needs and adds one major liability he can't afford.

Mydayis is mixed amphetamine salts (MAS) — chemically identical to Adderall: 75% d-amphetamine + 25% l-amphetamine, delivered as the same four salt components (dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate).

The differentiator is the delivery system. Mydayis uses a three-bead pulsatile release:

1. Bead 1 — Immediate-release (IR): Releases on contact with stomach acid (pH ~1-3). First peak at ~1-2 hours.
2. Bead 2 — Delayed-release (DR): pH-dependent enteric coating dissolves at duodenal pH (~5.5-6.0). Second peak at ~4-6 hours.
3. Bead 3 — Extended-release (ER): Higher-pH-threshold enteric coating dissolves further down the GI tract (pH ~7+). Third peak at ~10-12 hours.

Net effect: A roughly 16-hour duration of effect (vs Adderall XR's ~10-12 hour duration vs Adderall IR's ~4-6 hours). Plasma amphetamine levels stay therapeutic from ~1 hr post-dose through ~14-16 hr post-dose with only one daily dose.

Pharmacological underpinnings (carried from parent — same drug):

• TAAR1 agonism reverses DAT/NET polarity → cytosolic monoamines efflux out of the presynaptic terminal
• VMAT2 disruption collapses vesicular monoamine storage proton gradient
• Weak MAO-A inhibition raises cytosolic substrate pool further
• Net result: continuous, dose-dependent, non-quantal dopamine + norepinephrine release into the synapse — flooding (not phasic) signaling

For full mechanistic detail including the d/l isomer functional split and the modern Sulzer/Daws-lab vesicular-vs-reverse-transport debate, see adderall.md. Mydayis is the same drug.

Why three beads? Originally developed by Shire (now Takeda) as SHP-465. The clinical pitch was "one-and-done morning dosing for adults whose work day extends 14-16 hours" — finance, law, executive medicine. FDA approved 2017 for adults and adolescents 13+ with ADHD. Not approved for children <13 — the 16-hour duration was deemed inappropriate for school-age sleep architecture. This is precisely the regulatory signal that flags Dylan: sleep architecture concern is real and acknowledged by FDA in the labeling.